Fig. 1

a Correlation between 1,5-AG intensities determined using the non-targeted semi-quantitative mass spectrometry (MS)-based metabolomics platform and the 1,5-AG concentrations measured with the quantitative Glycomark biochemical assay in two plasma aliquots from the same patient. b Correlation between osmolality measurements of saliva performed using identical instruments but on two individual platforms (TRI and Metabolon) with a time interval of 2 years. c Correlation between 1,5-AG intensities determined using the non-targeted MS-based metabolomics platform and the 1,5-AG concentrations determined with Glycomark assay in saliva. d Scatterplot of Glycomark assay read-outs from saliva and galactose intensities determined using the non-targeted MS-based metabolomics platform